The vials for injection should be opened only immediately prior to use and any unused solution should be discarded.
Single dose vials are for single use only.
To reduce local discomfort, let the solution reach room temperature before injection. Avoid multiple injections at short intervals at the same site.
Prior to administration the solution should be inspected visually for changes of colour or solid particles.
Each vial contains a clear colourless solution, free from foreign matter.
It is not recommended to mix or dilute the Octreotide solutions for injection except with 0.9% Sodium Chloride solution.
Any unused solution or waste material should be disposed of in accordance with local requirements.
Each vial contains a clear colourless solution, free from foreign matter.
Single dose vials (50 micrograms/ml, 100 micrograms/ml and 500 micrograms/ml injection) are for single use only.
Subcutaneous injections
Patients who will be injecting themselves must receive precise instructions from the doctor or nurse.
To reduce local discomfort, let the solution reach room temperature before injection.
Avoid multiple injections at short intervals at the same site.
To prevent contamination, it is recommended that the cap of the multidose vial (200 micrograms /ml) should be punctured no more than 10 times.
Intravenous infusion
Prior to administration the solution should be inspected visually for changes of colour or solid particles. The diluted solutions of Octreotide Hospira (octreotide acetate) in 0.9% sodium chloride solution for injection and stored in PVC bags or in polypropylene syringes are physically and chemically stable for seven days when stored at below 25°C. From a microbiological point of view, the diluted solution should preferably be used immediately. If the solution is not used immediately, storage prior to use is the responsibility of the user and normally should not be longer than 24 hours at 2 to 8°C unless dilution has taken place in controlled and validated aseptic conditions. Before administration the solution has to be brought to room temperature again.
When Octreotide is to be administered as intravenous infusion, the contents of one 500 micrograms vial should normally be dissolved in 60 mL physiological saline, and the resulting solution should be infused by means of an infusion pump. This should be repeated as often as necessary until the prescribed duration of treatment is reached. Octreotide has also been infused in lower concentrations.
Any unused solution or waste material should be disposed of in accordance with local requirements.